Italy Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032

Italy Point-of-Care Glucose Testing Market

The Italy point-of-care glucose testing market has been witnessing significant growth during the forecast period, owing to increase in innovation and rise in technological advancement. Moreover, the continuous pursuit for accurate and user-friendly glucose testing tools is a key factor driving the market growth. However, challenges regarding reimbursements and the inherent intricacies of diabetes management are the key factors restraining the growth of the Italy point-of-care glucose testing market. The Italy point-of-care glucose testing market is segmented into product type, application, and end user. On the basis of product type, the market is classified into lancing devices & strips and blood-glucose meter. As per application, it is bifurcated into type-1 diabetes and type-2 diabetes. By end user, it is categorized into hospitals & clinics, home care settings, and others. On the contrary, surge in innovation is one of the key trends driving the market growth. Furthermore, the convergence of technology and healthcare promises to make glucose testing seamless, accurate, and patient-centric. In addition, companies are collaborating with healthcare providers and insurance companies to gain a competitive edge in the market. 

Moreover, companies are investing in R&D activities and product development to gain a competitive edge in the Italy point-of-care glucose testing market. Furthermore, manufacturers are actively seeking ways to minimize the environmental footprint of their products, incorporating sustainable packaging and implementing strategies to reduce waste in glucose testing process. In addition, key players in the market are collaborating to enhance their product portfolios and expand their market presence. This collaborative approach stimulates competition, fosters innovation, and promotes product diversification, ultimately providing end users with a broader selection of options. The Porter's five forces analysis assesses the competitive strength of the players in the point-of-care glucose testing market. These five forces include the threat of new entrants, the bargaining power of suppliers, the bargaining power of buyers, the threat of substitutes, and competitive rivalry. 

The threat of new entrants is high. The bargaining power of suppliers is moderate. The bargaining power of buyers is high. The threat of substitutes is moderate. The competitive rivalry is high. A SWOT analysis of the Italy point-of-care glucose testing market includes strengths, weaknesses, opportunities, and threats. Strengths include industry’s commitment to innovation, rise in prevalence of diabetes, and the market's adaptability. Weaknesses include the regulatory challenges that restrain the market growth and the inherent complexities of managing diabetes. Moreover, market players are often required to make substantial investments in R&D, which is a financial strain. Opportunities include the potential for technological breakthroughs and collaborations with healthcare providers. The market harnesses the power of data analytics and telemedicine to create integrated and efficient solutions for diabetes management. Threats include regulatory changes and reimbursement uncertainties.

Key players operating in the Italy point-of-care glucose testing market include Roche Diagnostics, Abbott Laboratories, Becton, Dickinson and Co., Bayer AG, Nova Biomedical Corporation, Beckman Coulter, Inc., EKF Diagnostics, HDI Diagnostics, Menarini Diagnostics and Arkray, Inc.

 Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in Italy point-of-care glucose testing market.

Assess and rank the top factors that are expected to affect the growth of Italy point-of-care glucose testing market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the Italy point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

● Product Benchmarking / Product specification and applications

○ Arkray, Inc

Scope of Italy Point-of-Care Glucose Testing Market Report

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits to the Stakeholders

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

2.1. CXO Perspective

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Impacting Factors

3.2.2. Top Investment Pockets

3.3. Porter’s Five Forces Analysis

3.4. Market Dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market Size and Forecast, By Product Type

4.2. Lancing Devices and Strips

4.3. Blood-Glucose Meter

5.1. Overview

5.1.1. Market Size and Forecast, By Application

5.2. Type-1 Diabetes

5.3. Type-2 Diabetes

6.1. Overview

6.1.1. Market Size and Forecast, By End User

6.2. Hospitals and Clinics

6.3. Home Care Settings

6.4. Others

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Top player positioning, 2022

8.1. Roche Diagnostics

8.1.1. Company overview

8.1.2. Key Executives

8.1.3. Company snapshot

8.1.4. Operating business segments

8.1.5. Product portfolio

8.1.6. Business performance

8.1.7. Key strategic moves and developments

8.2. Abbott Laboratories

8.2.1. Company overview

8.2.2. Key Executives

8.2.3. Company snapshot

8.2.4. Operating business segments

8.2.5. Product portfolio

8.2.6. Business performance

8.2.7. Key strategic moves and developments

8.3. Becton, Dickinson and Co.

8.3.1. Company overview

8.3.2. Key Executives

8.3.3. Company snapshot

8.3.4. Operating business segments

8.3.5. Product portfolio

8.3.6. Business performance

8.3.7. Key strategic moves and developments

8.4. Bayer AG

8.4.1. Company overview

8.4.2. Key Executives

8.4.3. Company snapshot

8.4.4. Operating business segments

8.4.5. Product portfolio

8.4.6. Business performance

8.4.7. Key strategic moves and developments

8.5. Nova Biomedical Corporation

8.5.1. Company overview

8.5.2. Key Executives

8.5.3. Company snapshot

8.5.4. Operating business segments

8.5.5. Product portfolio

8.5.6. Business performance

8.5.7. Key strategic moves and developments

8.6. Beckman Coulter, Inc.

8.6.1. Company overview

8.6.2. Key Executives

8.6.3. Company snapshot

8.6.4. Operating business segments

8.6.5. Product portfolio

8.6.6. Business performance

8.6.7. Key strategic moves and developments

8.7. EKF Diagnostics

8.7.1. Company overview

8.7.2. Key Executives

8.7.3. Company snapshot

8.7.4. Operating business segments

8.7.5. Product portfolio

8.7.6. Business performance

8.7.7. Key strategic moves and developments

8.8. HDI Diagnostics

8.8.1. Company overview

8.8.2. Key Executives

8.8.3. Company snapshot

8.8.4. Operating business segments

8.8.5. Product portfolio

8.8.6. Business performance

8.8.7. Key strategic moves and developments

8.9. Menarini Diagnostics

8.9.1. Company overview

8.9.2. Key Executives

8.9.3. Company snapshot

8.9.4. Operating business segments

8.9.5. Product portfolio

8.9.6. Business performance

8.9.7. Key strategic moves and developments

8.10. Arkray, Inc.

8.10.1. Company overview

8.10.2. Key Executives

8.10.3. Company snapshot

8.10.4. Operating business segments

8.10.5. Product portfolio

8.10.6. Business performance

8.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 02. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 03. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 04. ROCHE DIAGNOSTICS: KEY EXECUTIVES

TABLE 05. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 06. ROCHE DIAGNOSTICS: OPERATING SEGMENTS

TABLE 07. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 08. ROCHE DIAGNOSTICS: KEY STRATERGIES

TABLE 09. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 10. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 11. ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 12. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 13. ABBOTT LABORATORIES: KEY STRATERGIES

TABLE 14. BECTON, DICKINSON AND CO.: KEY EXECUTIVES

TABLE 15. BECTON, DICKINSON AND CO.: COMPANY SNAPSHOT

TABLE 16. BECTON, DICKINSON AND CO.: OPERATING SEGMENTS

TABLE 17. BECTON, DICKINSON AND CO.: PRODUCT PORTFOLIO

TABLE 18. BECTON, DICKINSON AND CO.: KEY STRATERGIES

TABLE 19. BAYER AG: KEY EXECUTIVES

TABLE 20. BAYER AG: COMPANY SNAPSHOT

TABLE 21. BAYER AG: OPERATING SEGMENTS

TABLE 22. BAYER AG: PRODUCT PORTFOLIO

TABLE 23. BAYER AG: KEY STRATERGIES

TABLE 24. NOVA BIOMEDICAL CORPORATION: KEY EXECUTIVES

TABLE 25. NOVA BIOMEDICAL CORPORATION: COMPANY SNAPSHOT

TABLE 26. NOVA BIOMEDICAL CORPORATION: OPERATING SEGMENTS

TABLE 27. NOVA BIOMEDICAL CORPORATION: PRODUCT PORTFOLIO

TABLE 28. NOVA BIOMEDICAL CORPORATION: KEY STRATERGIES

TABLE 29. BECKMAN COULTER, INC.: KEY EXECUTIVES

TABLE 30. BECKMAN COULTER, INC.: COMPANY SNAPSHOT

TABLE 31. BECKMAN COULTER, INC.: OPERATING SEGMENTS

TABLE 32. BECKMAN COULTER, INC.: PRODUCT PORTFOLIO

TABLE 33. BECKMAN COULTER, INC.: KEY STRATERGIES

TABLE 34. EKF DIAGNOSTICS: KEY EXECUTIVES

TABLE 35. EKF DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 36. EKF DIAGNOSTICS: OPERATING SEGMENTS

TABLE 37. EKF DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 38. EKF DIAGNOSTICS: KEY STRATERGIES

TABLE 39. HDI DIAGNOSTICS: KEY EXECUTIVES

TABLE 40. HDI DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 41. HDI DIAGNOSTICS: OPERATING SEGMENTS

TABLE 42. HDI DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 43. HDI DIAGNOSTICS: KEY STRATERGIES

TABLE 44. MENARINI DIAGNOSTICS: KEY EXECUTIVES

TABLE 45. MENARINI DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 46. MENARINI DIAGNOSTICS: OPERATING SEGMENTS

TABLE 47. MENARINI DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 48. MENARINI DIAGNOSTICS: KEY STRATERGIES

TABLE 49. ARKRAY, INC.: KEY EXECUTIVES

TABLE 50. ARKRAY, INC.: COMPANY SNAPSHOT

TABLE 51. ARKRAY, INC.: OPERATING SEGMENTS

TABLE 52. ARKRAY, INC.: PRODUCT PORTFOLIO

TABLE 53. ARKRAY, INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN ITALY POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)

FIGURE 04. PORTER FIVE-1

FIGURE 05. PORTER FIVE-2

FIGURE 06. PORTER FIVE-3

FIGURE 07. PORTER FIVE-4

FIGURE 08. PORTER FIVE-5

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: ITALY POINT-OF-CARE GLUCOSE TESTING MARKET

FIGURE 10. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)

FIGURE 11. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)

FIGURE 12. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)

FIGURE 13. TOP WINNING STRATEGIES, BY YEAR

FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 17. COMPETITIVE DASHBOARD

FIGURE 18. COMPETITIVE HEATMAP: ITALY POINT-OF-CARE GLUCOSE TESTING MARKET

FIGURE 19. TOP PLAYER POSITIONING, 2022

FIGURE 20. ROCHE DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)

FIGURE 21. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 22. ROCHE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 23. ABBOTT LABORATORIES: NET SALES, 2020-2022* ($MILLION)

FIGURE 24. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 25. ABBOTT LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 26. BECTON, DICKINSON AND CO.: NET SALES, 2020-2022* ($MILLION)

FIGURE 27. BECTON, DICKINSON AND CO.: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 28. BECTON, DICKINSON AND CO.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 29. BAYER AG: NET SALES, 2020-2022* ($MILLION)

FIGURE 30. BAYER AG: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 31. BAYER AG: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 32. NOVA BIOMEDICAL CORPORATION: NET SALES, 2020-2022* ($MILLION)

FIGURE 33. NOVA BIOMEDICAL CORPORATION: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 34. NOVA BIOMEDICAL CORPORATION: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 35. BECKMAN COULTER, INC.: NET SALES, 2020-2022* ($MILLION)

FIGURE 36. BECKMAN COULTER, INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 37. BECKMAN COULTER, INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 38. EKF DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)

FIGURE 39. EKF DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 40. EKF DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 41. HDI DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)

FIGURE 42. HDI DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 43. HDI DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 44. MENARINI DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)

FIGURE 45. MENARINI DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 46. MENARINI DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 47. ARKRAY, INC.: NET SALES, 2020-2022* ($MILLION)

FIGURE 48. ARKRAY, INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 49. ARKRAY, INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%